JESSICA MCCAFFERTY: Open Payments
NPI 1962844183 · FLORENCE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,318 in 66 payments from 26 companies in 2025. Trend: 2023 $0 · 2024 $942 · 2025 $1,318
Food & beverage: $1,318
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $323 |
| Janssen Biotech, Inc. | 6 | $129 |
| Merck Sharp & Dohme LLC | 5 | $115 |
| BeOne Medicines USA, Inc. | 5 | $94 |
| AstraZeneca Pharmaceuticals LP | 4 | $86 |
| ABBVIE INC. | 4 | $77 |
| Celgene Corporation | 3 | $76 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
Products named: PLUVICTO, KEYTRUDA, KISQALI, REBLOZYL, SCEMBLIX, IMFINZI, RYBREVANT, BRUKINSA.
Industry payments across AL — which companies pay providers there.
